A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)

NCT07119931 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

DRUG: lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital